NCT04085653 2026-04-14
Managed Access Programs for BYL719, Alpelisib
Novartis
Available
Clinical Trials
9 trialsNCT05948943 2026-04-14
EPIK-L1
Novartis
Phase 2/3 Recruiting
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT05038735 2026-04-08
EPIK-B5
Novartis
Phase 3 Active not recruiting
NCT05631795 2026-04-07
ALPINIST
Novartis
Phase 4 Completed
NCT04251533 2026-04-03
EPIK-B3
Novartis
Phase 3 Terminated
NCT04208178 2026-04-02
EPIK-B2
Novartis
Phase 3 Active not recruiting
NCT04544189 2026-04-02
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT01872260 2026-04-01
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Novartis
Phase 1/2 Active not recruiting